DK1438340T3 - Antistoffer mod KDR, deres fremstilling og anvendelser - Google Patents

Antistoffer mod KDR, deres fremstilling og anvendelser

Info

Publication number: DK1438340T3
Authority: DK; Denmark
Prior art keywords: disclosed; kdr; preparation; cdr; antibody
Prior art date: 2001-10-10

Application number

DK02800666.6T

Other languages

English (en)

Inventor

Andrew George Popplewell

Simon Peter Tickle

Karen Zinkewich-Peotti

Robert Kendall Morrison

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2002-10-10

Publication date

2010-11-22

2002-10-10 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2010-11-22 Application granted granted Critical

2010-11-22 Publication of DK1438340T3 publication Critical patent/DK1438340T3/da

Links

101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000055590 human KDR Human genes 0.000 abstract 1
229940126619 mouse monoclonal antibody Drugs 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Jellies, Jams, And Syrups (AREA)
Bakery Products And Manufacturing Methods Therefor (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

DK02800666.6T 2001-10-10 2002-10-10 Antistoffer mod KDR, deres fremstilling og anvendelser DK1438340T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0124317.9A GB0124317D0 (en)	2001-10-10	2001-10-10	Biological products
PCT/GB2002/004619 WO2003031475A2 (en)	2001-10-10	2002-10-10	Antibodies against kdr, their production and uses

Publications (1)

Publication Number	Publication Date
DK1438340T3 true DK1438340T3 (da)	2010-11-22

Family

ID=9923562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02800666.6T DK1438340T3 (da)	2001-10-10	2002-10-10	Antistoffer mod KDR, deres fremstilling og anvendelser

Country Status (24)

Country	Link
US (2)	US7452976B2 (da)
EP (1)	EP1438340B1 (da)
JP (2)	JP4323312B2 (da)
KR (2)	KR101018908B1 (da)
CN (1)	CN1568331A (da)
AT (1)	ATE482234T1 (da)
AU (1)	AU2002334135B8 (da)
BR (1)	BR0212756A (da)
CA (1)	CA2458464A1 (da)
CO (1)	CO5580838A2 (da)
DE (1)	DE60237778D1 (da)
DK (1)	DK1438340T3 (da)
EA (1)	EA010970B1 (da)
ES (1)	ES2351208T3 (da)
GB (1)	GB0124317D0 (da)
HU (1)	HUP0401618A3 (da)
IL (1)	IL160849A0 (da)
IS (1)	IS7173A (da)
MX (1)	MXPA04003274A (da)
NO (1)	NO20040987L (da)
NZ (1)	NZ532758A (da)
PL (1)	PL208848B1 (da)
WO (1)	WO2003031475A2 (da)
ZA (1)	ZA200401910B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0129105D0 (en) *	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
UY28424A1 (es)	2003-07-22	2005-02-28	Schering Ag	Anticuerpos rgi y usos de los mismos.
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
EA014226B1 (ru)	2004-07-26	2010-10-29	Байоджен Айдек Ма Инк.	Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7785591B2 (en)	2004-10-14	2010-08-31	Morphosys Ag	Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2345723A1 (en) *	2005-03-25	2011-07-20	National Research Council Of Canada	Method for isolation of soluble polypeptides
GB0520169D0 (en) *	2005-10-04	2005-11-09	Celltech R&D Ltd	Biological products
KR20080090408A (ko)	2005-11-30	2008-10-08	아보트 러보러터리즈	항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101439828B1 (ko) *	2005-11-30	2014-09-17	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
TWI551607B (zh)	2006-07-14	2016-10-01	Ａｃ免疫公司	人類化抗體
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
BRPI0809042B1 (pt)	2007-03-22	2021-08-31	Biogen Ma Inc.	Proteína de ligação a cd154 isolada, seu uso, e composição
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
PT2238166E (pt)	2007-10-05	2014-02-11	Genentech Inc	Utilização do anticorpo anti-amilóide beta em doenças oculares
CA2751477C (en)	2009-02-17	2019-08-27	Ucb Pharma S.A.	Antibody molecules having specificity for human ox40
CN101531718B (zh) *	2009-04-22	2011-11-02	中国人民解放军***军事医学研究所	抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
SG10201606462WA (en)	2009-09-24	2016-09-29	Ucb Pharma Sa	Bacterial host strain
GB201000587D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
GB201000590D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial host strain
GB201000591D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
WO2011130377A2 (en)	2010-04-15	2011-10-20	Abbott Laboratories	Amyloid-beta binding proteins
GB201012599D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Process for purifying proteins
RU2607368C2 (ru)	2010-07-30	2017-01-10	Ац Иммуне С.А.	Безопасные и функциональные гуманизированные антитела
CN103298833B (zh)	2010-08-14	2015-12-16	Abbvie公司	β淀粉样蛋白结合蛋白
LT2731973T (lt)	2011-07-13	2018-02-26	Ucb Biopharma Sprl	Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
MX356412B (es)	2011-11-02	2018-05-29	Apexigen Inc	Anticuerpos anti-kdr y metodos de uso.
UA112203C2 (uk)	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CN104220458B (zh)	2012-02-24	2018-08-14	阿特根公司	结合有含半胱氨酸残基的基序的修饰抗体，含该修饰抗体的修饰抗体-药物缀合物以及其制造方法
GB201208367D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Biological product
AU2013348570B2 (en)	2012-11-21	2017-01-12	Pharmabcine Inc.	Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same
AU2018255244A1 (en)	2017-04-21	2019-10-31	Mellitus, Llc	Methods and antibodies for diabetes-related applications
US20220031841A1 (en) *	2018-09-19	2022-02-03	Totient, Inc.	Cancer associated antibody compositions and methods of use
CN113454120A (zh) *	2018-12-20	2021-09-28	阿尔伯特爱因斯坦医学院	针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en)	1989-02-10	1989-03-30	Celltech Ltd	Chemical compounds
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
CN1701814A (zh)	1992-11-13	2005-11-30	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k－1
DE19638745C2 (de) *	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6133426A (en)	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
CA2293723A1 (en)	1997-06-18	1998-12-23	Merck & Co., Inc.	Human receptor tyrosine kinase, kdr
CA2328893A1 (en) *	1998-05-20	1999-11-25	Kyowa Hakko Kogyo Co., Ltd.	Vegf activity inhibitors
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
WO2000044777A1 (en)	1999-01-29	2000-08-03	Imclone Systems Incorporated	Antibodies specific to kdr and uses thereof

2001
- 2001-10-10 GB GBGB0124317.9A patent/GB0124317D0/en not_active Ceased
2002
- 2002-10-10 WO PCT/GB2002/004619 patent/WO2003031475A2/en active Application Filing
- 2002-10-10 EA EA200400519A patent/EA010970B1/ru not_active IP Right Cessation
- 2002-10-10 AU AU2002334135A patent/AU2002334135B8/en not_active Ceased
- 2002-10-10 EP EP02800666A patent/EP1438340B1/en not_active Expired - Lifetime
- 2002-10-10 JP JP2003534457A patent/JP4323312B2/ja not_active Expired - Fee Related
- 2002-10-10 PL PL370344A patent/PL208848B1/pl not_active IP Right Cessation
- 2002-10-10 CA CA002458464A patent/CA2458464A1/en not_active Abandoned
- 2002-10-10 NZ NZ532758A patent/NZ532758A/en not_active IP Right Cessation
- 2002-10-10 HU HU0401618A patent/HUP0401618A3/hu unknown
- 2002-10-10 US US10/492,228 patent/US7452976B2/en not_active Expired - Fee Related
- 2002-10-10 KR KR1020047005051A patent/KR101018908B1/ko not_active IP Right Cessation
- 2002-10-10 ES ES02800666T patent/ES2351208T3/es not_active Expired - Lifetime
- 2002-10-10 BR BR0212756-3A patent/BR0212756A/pt not_active IP Right Cessation
- 2002-10-10 DK DK02800666.6T patent/DK1438340T3/da active
- 2002-10-10 CN CNA028202104A patent/CN1568331A/zh active Pending
- 2002-10-10 IL IL16084902A patent/IL160849A0/xx not_active IP Right Cessation
- 2002-10-10 AT AT02800666T patent/ATE482234T1/de not_active IP Right Cessation
- 2002-10-10 MX MXPA04003274A patent/MXPA04003274A/es active IP Right Grant
- 2002-10-10 KR KR1020077023689A patent/KR20070116110A/ko not_active Application Discontinuation
- 2002-10-10 DE DE60237778T patent/DE60237778D1/de not_active Expired - Lifetime
2004
- 2004-03-05 IS IS7173A patent/IS7173A/is unknown
- 2004-03-08 NO NO20040987A patent/NO20040987L/no not_active Application Discontinuation
- 2004-03-09 ZA ZA200401910A patent/ZA200401910B/en unknown
- 2004-05-06 CO CO04041969A patent/CO5580838A2/es not_active Application Discontinuation
2007
- 2007-10-30 US US11/928,880 patent/US7842787B2/en not_active Expired - Fee Related
2008
- 2008-11-18 JP JP2008294819A patent/JP2009108086A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ZA200401910B (en)	2005-03-09
HUP0401618A3 (en)	2012-03-28
EP1438340A2 (en)	2004-07-21
KR20040097983A (ko)	2004-11-18
KR20070116110A (ko)	2007-12-06
AU2002334135B8 (en)	2009-01-29
WO2003031475A2 (en)	2003-04-17
BR0212756A (pt)	2004-11-16
EA010970B1 (ru)	2008-12-30
KR101018908B1 (ko)	2011-03-02
AU2002334135B2 (en)	2009-01-08
US20050181448A1 (en)	2005-08-18
NO20040987L (no)	2004-05-10
DE60237778D1 (de)	2010-11-04
US7842787B2 (en)	2010-11-30
JP4323312B2 (ja)	2009-09-02
ATE482234T1 (de)	2010-10-15
JP2005516590A (ja)	2005-06-09
PL370344A1 (en)	2005-05-16
HUP0401618A2 (hu)	2004-11-29
US7452976B2 (en)	2008-11-18
PL208848B1 (pl)	2011-06-30
IS7173A (is)	2004-03-05
CO5580838A2 (es)	2005-11-30
EA200400519A1 (ru)	2004-12-30
ES2351208T3 (es)	2011-02-01
IL160849A0 (en)	2004-08-31
CA2458464A1 (en)	2003-04-17
MXPA04003274A (es)	2004-07-08
EP1438340B1 (en)	2010-09-22
WO2003031475A8 (en)	2004-10-14
WO2003031475A3 (en)	2004-03-25
NZ532758A (en)	2008-04-30
GB0124317D0 (en)	2001-11-28
US20090269840A1 (en)	2009-10-29
JP2009108086A (ja)	2009-05-21
CN1568331A (zh)	2005-01-19

Publication	Publication Date	Title
DK1438340T3 (da)	2010-11-22	Antistoffer mod KDR, deres fremstilling og anvendelser
LTPA2017043I1 (lt)	2018-01-10	Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
AP2092A (en)	2010-02-28	Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
CY1118443T1 (el)	2017-06-28	Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PT2305715T (pt)	2017-03-02	Anticorpo monoclonal para a proteína de ligação a osteoprotegerina